Earnings Releases·Nov 3, 2026, 4:08 PM ET

Contineum Therapeutics — Third Quarter 2026 Earnings Summary

Net loss widened to $18.7 million for the quarter ended September 30, 2026, compared to $12.8 million in the prior year period, driven by a 45% increase in R&D expenses to $16.0 million and a 26% rise in G&A expenses to $5.0 million.
The company maintains a robust liquidity position with $244.5 million in cash, cash equivalents, and marketable securities, projecting a cash runway extending through mid-2029.
The PROPEL-IPF Phase 2 trial for PIPE-791 continues enrollment at over 100 sites across 16 countries, with management expressing confidence in the trial's progress and the clinical validation of the LPAR1 target class.
No revenue was generated during the quarter, consistent with the company's clinical-stage status, while the weighted-average shares outstanding increased to 38.4 million from 28.1 million in the prior year period.